An Allogeneic Multiple Myeloma GM-CSF-Secreting Vaccine with Lenalidomide Induces Long-term Immunity and Durable Clinical Responses in Patients in Near Complete Remission.
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500
Informations de publication
Date de publication:
15 12 2021
15 12 2021
Historique:
received:
25
05
2021
revised:
29
07
2021
accepted:
24
09
2021
pubmed:
21
10
2021
medline:
8
4
2022
entrez:
20
10
2021
Statut:
ppublish
Résumé
This proof-of-principle clinical trial evaluated whether an allogeneic multiple myeloma GM-CSF-secreting vaccine (MM-GVAX) in combination with lenalidomide could deepen the clinical response in patients with multiple myeloma in sustained near complete remission (nCR). Fifteen patients on lenalidomide were treated with MM-GVAX and pneumococcal conjugate vaccine (PCV; Prevnar) at 1, 2, 3, and 6 months. Eight patients (53.3%) achieved a true CR. With a median follow-up of 5 years, the median progression-free survival had not been reached, and the median overall survival was 7.8 years from enrollment. MM-GVAX induced clonal T-cell expansion and measurable cytokine responses that persisted up to 7 years in all patients. At baseline, a higher minimal residual disease was predictive of early relapse. After vaccination, a lack of both CD27 MM-GVAX, along with lenalidomide, effectively primed durable immunity and resulted in long-term disease control, as suggested by the reappearance of a detectable, fluctuating M-spike without meeting the criteria for clinical relapse. For patients in a nCR, MM-GVAX administration was safe and resulted in prolonged clinical responses.
Identifiants
pubmed: 34667029
pii: 1078-0432.CCR-21-1916
doi: 10.1158/1078-0432.CCR-21-1916
pmc: PMC8678348
mid: NIHMS1745854
doi:
Substances chimiques
Cancer Vaccines
0
Granulocyte-Macrophage Colony-Stimulating Factor
83869-56-1
Lenalidomide
F0P408N6V4
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
6696-6708Subventions
Organisme : NCI NIH HHS
ID : K08 CA218893
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA006973
Pays : United States
Informations de copyright
©2021 American Association for Cancer Research.
Références
Cancer Discov. 2019 Apr;9(4):476-481
pubmed: 30862723
N Engl J Med. 2012 May 10;366(19):1782-91
pubmed: 22571202
Nat Commun. 2017 May 24;8:15221
pubmed: 28537262
Haematologica. 2011 Apr;96(4):574-82
pubmed: 21173094
J Immunol. 2011 Jul 15;187(2):1047-56
pubmed: 21677134
Nat Commun. 2018 Feb 21;9(1):741
pubmed: 29467463
Immunity. 2020 Oct 13;53(4):824-839.e10
pubmed: 33053331
Int Immunopharmacol. 2018 Sep;62:29-39
pubmed: 29990692
Nat Immunol. 2020 Apr;21(4):412-421
pubmed: 32066954
Nat Rev Immunol. 2018 Mar;18(3):168-182
pubmed: 29226910
Nature. 2007 Dec 6;450(7171):903-7
pubmed: 18026089
Cancer Discov. 2018 Dec;8(12):OF6
pubmed: 30327352
Br J Haematol. 1998 Sep;102(5):1115-23
pubmed: 9753033
Clin Cancer Res. 2012 Mar 1;18(5):1426-34
pubmed: 22241792
Clin Cancer Res. 2016 Jun 15;22(12):2885-96
pubmed: 26873960
Blood. 2018 Jun 14;131(24):2640-2650
pubmed: 29728403
Proc Natl Acad Sci U S A. 2014 Jun 24;111(25):9229-34
pubmed: 24927527
Haematologica. 2020 Jul;105(7):1937-1947
pubmed: 31582542
Blood. 2009 Nov 5;114(19):4099-107
pubmed: 19706884
N Engl J Med. 2021 Feb 25;384(8):705-716
pubmed: 33626253
Nat Commun. 2013;4:2680
pubmed: 24157944
Hematology Am Soc Hematol Educ Program. 2014 Dec 5;2014(1):255-61
pubmed: 25696864
J Clin Oncol. 2017 Oct 10;35(29):3279-3289
pubmed: 28742454
Leukemia. 2016 Apr;30(4):929-36
pubmed: 26639181
JCI Insight. 2019 Apr 23;5:
pubmed: 31013254
J Immunol. 2010 Nov 1;185(9):4988-92
pubmed: 20935204
J Exp Med. 2007 Apr 16;204(4):831-40
pubmed: 17389240
F1000Res. 2017 May 26;6:748
pubmed: 28663787
Eur J Immunol. 2019 Jun;49(6):853-872
pubmed: 30891737
Hum Gene Ther. 1999 Aug 10;10(12):1983-91
pubmed: 10466632
Blood. 2012 Aug 30;120(9):1801-9
pubmed: 22665938
J Clin Oncol. 2021 Feb 10;39(5):433-443
pubmed: 33434056
Clin Cancer Res. 2013 Jul 1;19(13):3640-8
pubmed: 23685836
Nature. 2019 Jan;565(7739):366-371
pubmed: 30598548
Blood Adv. 2020 Jul 28;4(14):3295-3301
pubmed: 32706892
N Engl J Med. 2017 Apr 6;376(14):1311-1320
pubmed: 28379796
Nature. 2019 Oct;574(7780):696-701
pubmed: 31645760
Haematologica. 2019 Jul;104(7):1440-1450
pubmed: 30733268
Blood. 2016 Jun 16;127(24):2955-62
pubmed: 27002115
Blood. 2011 Jan 13;117(2):393-402
pubmed: 21030562
N Engl J Med. 2019 May 2;380(18):1726-1737
pubmed: 31042825
Semin Immunopathol. 2019 Jan;41(1):69-85
pubmed: 29978248
Immunity. 2020 May 19;52(5):825-841.e8
pubmed: 32396847
Cancer Res. 2004 Sep 1;64(17):6337-43
pubmed: 15342423
Nat Rev Immunol. 2019 Nov;19(11):665-674
pubmed: 31570879
Lancet Oncol. 2016 Aug;17(8):e328-e346
pubmed: 27511158
J Clin Oncol. 2008 Dec 10;26(35):5775-82
pubmed: 19001321
N Engl J Med. 2011 Mar 17;364(11):1046-60
pubmed: 21410373
PLoS One. 2016 Aug 11;11(8):e0160853
pubmed: 27513338
J Exp Med. 1997 Jul 7;186(1):65-70
pubmed: 9206998
Lancet. 2017 Feb 4;389(10068):519-527
pubmed: 28017406
Cytokine Growth Factor Rev. 2002 Apr;13(2):185-93
pubmed: 11900993
J Exp Med. 2008 Dec 22;205(13):2965-73
pubmed: 19029380
Blood. 2018 Dec 6;132(23):2456-2464
pubmed: 30249784
Mol Oncol. 2015 Dec;9(10):2063-70
pubmed: 26404496
Nat Immunol. 2021 Jul;22(7):865-879
pubmed: 34140678
J Clin Oncol. 2015 Sep 10;33(26):2863-9
pubmed: 26240224
J Immunol Methods. 2012 Jan 31;375(1-2):14-9
pubmed: 21945395
JAMA Oncol. 2017 Jan 1;3(1):28-35
pubmed: 27632282